

Dear ECST-2 Investigators

We are pleased to send you the **June Newsletter for the ECST-2 Study**.

We are very grateful for your swift feedback and cooperation in solving the queries regarding the 2-year follow-up visit and the discrepancies in imaging dates.

Whenever possible, please continue with the study visits as scheduled in the trial protocol

Please note the following:

- In the event that the patient is in a high-risk group for COVID-19 or who is self-isolating or in whom clinical follow-up visits are not possible, please perform the visits by telephone (or e.g. face-time or whatsapp) and write a note in the comment box.
- As soon as the post service to the trial office has reopened, we will send you a list with all missing CD-images.
- Maintaining a high patient retention in the study is very important. For this reason, we will send you detailed advice on how to follow-up patients who have not returned for scheduled visits. We need to find out about their **vital status**.

Many thanks for your understanding and cooperation.

We all appreciate your hard work and efforts in support of the ECST-2 Study under all the special circumstances.

With best regards of the Trial Management Team

Prof. Martin Brown, MD
Chief-Investigator London

Ekaterina Biggs
Trial Manager (Trial Office London) ECST-2

Prof. Leo Bonati, MD
Co-Chief Investigator Basel

Marina Maurer
Trial Manager (Basel office) ECST-2

Dr. Paul Nederkoorn, MD
Co-Chief Investigator Amsterdam

Laurine van der Steen
Trial Manager (Amsterdam office) ECST-2



Trial Manager (Basel office) ECST-2

Marina Maurer

Petersgraben 4

CH-4031 Basel

Switzerland

Phone +41 61 55 65030

Fax +41 61 265 2995

E-Mail: marina.maurer@usb.ch

Website: www.usb.ch



Bitte denken Sie an die Umwelt, bevor Sie dieses E-Mail ausdrucken!

VUmc disclaimer : www.vumc.nl/disclaimer
AMC disclaimer : www.amc.nl/disclaimer